International Journal of Immunotherapy and Cancer Research is a multi-disciplinary peer-reviewed, open access journal. Journal brings together all the varied aspects of research that will ultimately lead to the prevention of cancer. With the goal of advancing technology and improving healthRead more
Research interests: Carcinoma Unknown Primary Cancer of Unknown Primary (CUP) is the term applied to metastatic cancer of which the origin remains unidentified. Since treatment is usually based on the profile of the primary cancer, treatment of these patients is a challenge. Reports on incidence, treatment, and survival are limited. My personal challenge is to increase the awareness with regard to CUP via research and support patients suffering from CUP, as well as the patients' family and friends. Prostate cancer. Prostate cancer is a disease of elderly males. An increase in prostate cancer is expected in the coming years due to a growing population of men aged over 60 years of age from 475 million in 2009 to 1.6 billion in the year 2050 worldwide. Moreover, if screening for prostate cancer is taken into account, even more men will be diagnosed with this disease. Immunotherapy, especially the role of Interleukin 7 and TGFbeta
Research Interest: Cancer immunotherapy, antigen presentation, dendritic
cells, costimulatory molecule AND cancer vaccine.
Research Interest: Immunophenotyping, Immunocytochemistry, Multilineag differentiation, RNA isolation, RT- PCR, Cancer cell line, Immunocytochemistry, Real-Time PCR, Western blot, Transport mechanism by liquid santillation Counter, Induction of leukemia in experimental animal, Biochemical enzymatic analysis, TEM analysis, Histopathology, RT-PCR, apoptosis analysis, Western blot, MTT assay, Measurement of intracellular ROS, Analysis of mitochondrial membrane potential, Intracellular calcium levels, Quantiﬁcation of endogenous GSH, DNA fragmentation, Column Chromatography, Antibiotic sensitivity assay, Extract preparation, Antibiotic sensitivity assay
Research Interest: Melanoma, kidney cancer , immunotherapy with ipilimumab, nivolumab, interleukin-2 and other agents.
Research Interest: Lab Medicine, Clinical Chemistry, Endocrinology and Immunology.
Research Interest: Cancer therapy, cancer stem cells, tumour biomarkers, suicide gene therapy and antitumoral drugs, nanotechnology and regenerative medicine.
Research Interest: Cancer biology, Cell culture, and Molecular biology
Research Interest: RNA interefence, Immunotherapy and Immunodiagnostics
Research Interest: Cancer Genomics and Transcriptomics, Mesenchymal Stem cell culture, characterization and profiling from various sources, in vitro and ex-vivo human breast cancer explants, drug screening in in vitro system.
Research Interest: These cancers express unique tumor-specific or
-associated antigens to which my lab directs T cell immune responses via DNA,
RNA, protein or peptide based vaccines.
Vaccine components are delivered in their native form, by dendritic
cells, by recombinant Adeno Associated Virus.
This clinically translational research is backed up by pre-clinical and
basic research in both normal and transgenic animal models and in laboratory
studies on patient material. Results from the pre-clinical studies have led to a variety of clinical trials
for which I am the immunological coordinator.
Research Interest: Research areas of human physiology and pathophysiology. His research focuses on the clinical evaluation of new biomarkers and molecular mediators in several pathophysiological disease states, such as diabetes, atherosclerosis and cancer. His research interest also includes the development of quantitative structure-activity relationships (QSARs) and quantitative structure-property relationships (QSPRs) in the area of toxicology and pharmacology. Furthermore, his research interest lies in the assessment of physicochemical properties, such as lipophilicity, solubility and ionization of drugs, natural bioactive compounds and toxic chemicals in relation with their potential biological activity and toxicity endpoints, as well as their Absorption/Distribution/Metabolism/Excretion (ADME) parameters and their pharmacokinetic and toxicokinetic profiles
Research Interest: Radiopharmaceutical development that involves radiolabeled agents and
their evaluations both in vitro and in vivo. These agents are for disease
detection, life process tracing, or tumor radiotherapy.
Research Interest: Oral Sciences, Oral Pathology, Molecular Biology, Cancer Biology, Histochemistry
Research Interest: Leukemia and lymphoma – clinical aspects, Adjuvant treatments in malignant hemopathies (e.g. resveratrol, statins), Connections between malignant hemopathies and dyslipidemia or metabolic syndrome, Thrombin generation in malignant hemopathies
Research Interest: 1) mTOR signaling, inflammation and hematopoiesis; (2) Neoplasm, hematologic cancers and related disorders; (3) Experimental cancer biology and clinical oncology; (4) Molecular mechanisms regulating hematopoietic stem cells function; (5) Molecular mechanisms involved in T / B / myeloid/erythroid cells developments; (6) Ubiquitination, apoptosis and selective autophagy.
Published On: February 03, 2017 | Pages: 012 - 014View Article DOI: 10.17352/2455-8591.000013
Published On: February 01, 2017 | Pages: 007 - 011View Article DOI: 10.17352/2455-8591.000012
Published On: February 01, 2017 | Pages: 001 - 006View Article DOI: 10.17352/2455-8591.000011
Published On: December 31, 2016 | Pages: 014 - 016View Article DOI: 10.17352/2455-8591.000010
Published On: October 06, 2016 | Pages: 011 - 013View Article DOI: 10.17352/2455-8591.000009
Published On: June 17, 2016 | Pages: 003 - 010View Article DOI: 10.17352/2455-8591.000008
Published On: January 23, 2016 | Pages: 001 - 002View Article DOI: 10.17352/2455-8591.000007
Published On: October 28, 2015 | Pages: 021 - 028View Article DOI: 10.17352/2455-8591.000006
Published On: October 13, 2015 | Pages: 018 - 022View Article DOI: 10.17352/2455-8591.000005
Published On: September 03, 2015 | Pages: 013 - 017View Article DOI: 10.17352/2455-8591.000004